Anavex indsender ansøgning til EMA den 26. november 2024!!
-
Teknisk er den ikke vendt endnu, kursudviklingen må gerne forholde sig i nuværende leje, så momentum/RSI kan falde ned og stabilisere sig på et lidt lavere niveau frem mod næste run. Det giver samtidig det glidende gennemsnit tid til at vende. Det passer perfekt med en begyndende optur i starten af marts hen mod konferencen i start april. Vi må se, mit gæt er ligeså godt som dit
-
Lidt fra Ariana pharma
https://www.arianapharma.com/anavex/?trk=public_post_comment-text -
Fra en facebook gruppe, lidt om ejerforhold. De udtrykker tilfredshed med det
Fra IHUB
Invesco Ltd. melder om 2,419,76% stigning i ejerskabet af AVXL / Anavex Life Sciences Corp.
Den 13. februar 2025 - Invesco Ltd. indgav en 13F-HR-formular, der afslørede ejerskabet af 615.048 aktier i Anavex Life Sciences Corp. (US:AVXL) værdi til $6.605.616 pr. 31. december 2024. Enheden indsendte en tidligere 13F-HR den 12. november 2024 og afslørede 24.409 aktier i Anavex Life Sciences Corp.. Dette svarer til en ændring i aktierne på 2.419,76% i løbet af kvartalet. Positionens nuværende værdi er $5.240,209 USD. -
Artikel om ny forståelse af Alzheimers:
ASU researchers propose unifying model of Alzheimer’s disease | ASU News
In a groundbreaking theory, scientists at Arizona State University's Biodesign Institute propose a unifying explanation for the molecular chaos driving Alzheimer's disease. The condition causes widespread disruption of gene behavior, affecting every known neuropathology and clinical manifestation of the disease.
(news.asu.edu)
-
Det er ikke en ny forståelse, at kronisk stress i høj grad indgår som en medvirkende faktor ved Alzheimer. Det har neurologer og hjerneforskere haft forståelse af i mange år.
Det nye i teorien er måske selve den detaljerede præcisering, at kronisk stress tidligt i livet kan forårsage udbredt forstyrrelse af genadfærden, som påvirker enhver neuropatologi og klinisk manifestation af sygdommen.
Der findes megen litteratur om emnet samt utal af faglige videoer på Youtube bla. denne:
-
Nogle prøver med en underskriftsindsamling:
Sign the Petition
A safe new Alzheimer's drug has been developed. It is called Blarcamesine.For the past few years, the FDA has been reluctant to accept the application for approval of this new drug, Blarcamesine. Blarcamesine has demonstrated tremendous effectiveness in slowing down the cognitive decline of those suffering Alzheimer's Disease. In other words, the drug allows your mother to remember who you are …
Change.org (www.change.org)
-
Rapporten præsenterer og viser en dynamisk vision af det globale scenario med hensyn til markedsstørrelse, markedsstatistikker og konkurrencesituation.
Har ikke læst den - kræver adgang. Sikkert en noget farvet præsentation? -
resumet nævner en forventet 3,8% vækst i market for Blarcamesine; men det er jo bare lig væksten i antal demente som beskrevet her: https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
Tænker partner aftaler og evnen til at skalere produktion og distribution må være det afgørelsen hvis blacamesine bliver godkendt i EMA og FDA
-
Cognition kom med en god nyhed i dag. Burde ikke rykke så meget i aktien, idet det var midtvejsresultater.
Men se hvad aktien laver i premarket:
https://www.nasdaq.com/market-activity/stocks/cgtx/pre-marketUS markedet er lige så sygt som deres politiske system - længere er den ikke !
-
Jeg ser lidt LinkedIN flirting fra MIsslinger omkring en mere generel usecase for Blarcamesine mod "mitochondrial degradation" som ogsaa kan have impact pa en raekke andre kedelige problemer - kunne der vaere et bredere link til Longevity med Blarcamesine ?
-
Det er jeg slet ikke i tvivl om.
Men der skal mange flere og længerevarende forsøg til at overbevise masserne.
Det Blarcamesine gør er, at at få vores aldrende krop til at fungere som en yngre model - mest gennem forbedret autophagy, at rydde op i dårlige celler og proteinaffald. Disse celler mv gør, at vi til sidst går til grunde.
Men læs hellere Mayomobiles analyse:
https://www.sotcanalytics.com/home -
Interessant short update:
https://stocktwits.com/J60611/message/605899410Krydser fingre
-
The silent warning sign of Alzheimer's you never saw coming ...
Alzheimer's disease has long been recognized as a progressive neurodegenerative disorder, but new research is reshaping our understanding of its development. Scientists have uncovered a hidden phase of the disease-one that begins silently, decades before symptoms appear.
Researchers have identified two distinct phases. The first, known as the "silent phase," can last 10 to 20 years before noticeable cognitive symptoms appear. During this time, subtle cellular changes take place, setting the stage for full-blown neurodegeneration.
The second phase is marked by a rapid escalation of brain damage, leading to memory loss, confusion, and other symptoms associated with Alzheimer's.
Understanding these two stages allows scientists to explore new ways to slow or even halt the disease before it reaches its more aggressive form.
Researchers found that the first major sign of the disease is the loss of a specific type of brain cell known as somatostatin inhibitory neurons. These neurons play a key role in regulating brain signals, and their disappearance appears to trigger a chain reaction leading to cognitive decline. Oligodendrocytes, which support nerve function, also begin to decline, slowing down communication between brain cells. https://lnkd.in/ehMESNk3
Both type of cells are believed to correlate with SIGMAR1 function, which activation restores impaired autophagy, which anticipates the neurodegenerative process in Alzheimer's disease. https://lnkd.in/evnUfNTm
The discovery of the silent phase could shifting the focus to early detection and prevention.
For patients and families affected by Alzheimer's, this research offers hope for earlier intervention and better treatment options.
The recognition of Alzheimer's as a two-phase condition is a major step forward, opening doors to potentially earlier, more effective intervention.
To learn more: https://lnkd.in/et4QWsrk
The following might be relevant in this context:
Both Anavex's Precision Medicine (PM) potential treatments for Alzheimer's disease, oral blarcamesine (ANAVEX2-73) and oral ANAVEX3-71 demonstrated preventing cognitive decline in respective animal models of Alzheimer's disease prevention. [https://www.anavex.com]
Furthermore, Precision Medicine (PM) oral once daily blarcamesine for early Alzheimer's disease (AD), exhibited a favorable safety profile over four (4) years, demonstrating no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13.
To learn more: https://lnkd.in/eZMgFw78
-
Følger ham også på LinkedIn - han har godt været aktiv de seneste par uger. Er han i panik ?
-
Mon dog. Men jeg ved ikke hvorfor han pludselig er så aktiv.
Men faktum er, at alt for få kender Anavex. Det er måske det han prøver at afhjælpe.
Dagens indslag blev f.eks. kommenteret af en organisation med over 3000 følgere.
Indlægget i dag er for mig meget interessant og her nævner Missling også, at fokus skal rettes imod profylakse behandling.
Jeg er meget optimistisk mht fremtidig tidlig behandling og evt helt at kunne modvirke, at alzheimers udvikler sig. Det kan være stort.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind